000120084 001__ 120084
000120084 005__ 20240319081018.0
000120084 0247_ $$2doi$$a10.3390/vaccines10101766
000120084 0248_ $$2sideral$$a130830
000120084 037__ $$aART-2022-130830
000120084 041__ $$aeng
000120084 100__ $$0(orcid)0000-0003-2313-2762$$aHernández-García, I.
000120084 245__ $$aInfluenza vaccination among multiple sclerosis patients during the COVID-19 pandemic
000120084 260__ $$c2022
000120084 5060_ $$aAccess copy available to the general public$$fUnrestricted
000120084 5203_ $$aIn the context of the COVID-19 pandemic, the co-circulation of influenza and SARS-CoV-2 viruses may have severe complications for vulnerable populations. For this reason, the World Health Organization pointed to the 2020–2021 anti-influenza campaign as being of special relevance. Our aim was to assess the 2020–2021 influenza vaccination coverage, and its associated factors, among patients in a Spanish multiple sclerosis (MS) unit. A cross–sectional study was conducted. People attending the MS unit of the Clinical Hospital of Zaragoza during 2020 were included. Variables were obtained by reviewing records. Associations with 2020–2021 influenza vaccination were analyzed using bivariate analysis and a multiple logistic regression model. A total of 302 patients were studied; 62.6% were women, whose mean age (standard deviation) was 47.3 (11.5) years. The 2020–2021 influenza vaccination coverage was 55.3% (59.8% in women and 47.8% in men). A total of 89.7% had at least one other indication for vaccination (e.g., immunosuppressive treatment in 225 patients). The variables associated with getting vaccinated were being female (adjusted odds ratio (95% confidence interval) (aOR (95%CI) = 2.12 (1.12–3.99)), having received the 2019–2020 influenza vaccine (aOR (95%CI) = 31.82 (14.71–68.86)) and being born in Spain (aOR (95%CI) = 12.91 (1.07–156.28)). Coverage is moderate compared to other countries. It is necessary to develop strategies to improve it, especially in men and those born outside Spain.
000120084 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000120084 590__ $$a7.8$$b2022
000120084 592__ $$a1.655$$b2022
000120084 591__ $$aMEDICINE, RESEARCH & EXPERIMENTAL$$b24 / 136 = 0.176$$c2022$$dQ1$$eT1
000120084 593__ $$aDrug Discovery$$c2022$$dQ1
000120084 591__ $$aIMMUNOLOGY$$b32 / 161 = 0.199$$c2022$$dQ1$$eT1
000120084 593__ $$aImmunology$$c2022$$dQ1
000120084 593__ $$aPharmacology (medical)$$c2022$$dQ1
000120084 593__ $$aPharmacology$$c2022$$dQ1
000120084 593__ $$aInfectious Diseases$$c2022$$dQ1
000120084 594__ $$a7.0$$b2022
000120084 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000120084 700__ $$0(orcid)0000-0002-1756-5492$$aGarcés Redondo, M.$$uUniversidad de Zaragoza
000120084 700__ $$aEspinosa Rueda, J.$$uUniversidad de Zaragoza
000120084 700__ $$aRodríguez-Montolio, J.$$uUniversidad de Zaragoza
000120084 700__ $$aBengoa-Urrengoechea, I.
000120084 700__ $$0(orcid)0000-0001-9714-8105$$aAibar Remón, C.$$uUniversidad de Zaragoza
000120084 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000120084 7102_ $$11011$$2615$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Medic.Prevent.Salud Públ.
000120084 773__ $$g10, 10 (2022), 1766[9 pp.]$$tVaccines$$x2076-393X
000120084 8564_ $$s294601$$uhttps://zaguan.unizar.es/record/120084/files/texto_completo.pdf$$yVersión publicada
000120084 8564_ $$s2722956$$uhttps://zaguan.unizar.es/record/120084/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000120084 909CO $$ooai:zaguan.unizar.es:120084$$particulos$$pdriver
000120084 951__ $$a2024-03-18-15:54:18
000120084 980__ $$aARTICLE